Top

Published in:

Open Access 01-12-2022 | Migraine | Research

A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Authors: Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi, Takao Takeshima, Takeo Nakayama, Hiromi Sano, Hiroyuki Kondo, Yoshiyuki Shibasaki, Nobuyuki Koga

Published in: The Journal of Headache and Pain | Issue 1/2022

Abstract

Background

Migraine is a chronic disease characterized by episodic headache attacks. No recent studies have, however been conducted on the epidemiology of migraine or the treatment landscape in Japan. This study was conducted as a fact-finding survey using medical claims data and an online survey on migraine and headaches, conducted among members of health insurance associations with the objective of gaining an understanding of migraine prevalence and the treatment status in Japan.

Methods

The study methodology utilized a unique approach of combined data sources. The data sources used in this study are medical claims data and linked online survey data provided by DeSC Healthcare Inc (DeSC). The primary outcomes (from survey responses) were: the overall number and proportion of migraine patients; and the overall prevalence of migraine, stratified by age and sex. The secondary outcomes (from survey responses) were use of medical care; and clinical features/headache symptoms. The analysis population included all individuals who had response data for surveys conducted by DeSC. The online survey data and medical claims data were summarized.

Results

The data population comprised 21,480 individuals. On the basis of the survey results, including probable cases, the overall prevalence of migraine was 3.2%. The highest prevalence of migraine was observed in patients aged 30–39 years. The prevalence of migraine in women was 4.4 times higher than in men. The percentage of migraine patients who had not been seen by a doctor was 81.0%. More than 80% of patients were taking over-the-counter drugs and 6.1% took prescription medicines only. Approximately 52.9% of patients considered that the intensity of pain symptoms was severe. Moreover, the majority of patients (72.9%) considered that the impairment of daily life activities was of moderate or severe degree.

Conclusions

In Japan, the percentage of people with migraine who did not receive medical attention is as high as 80%. Additionally, the majority of patients tend to endure symptoms and continue with everyday activities. With innovative treatment approaches becoming available it is necessary to disseminate information that migraine is not a simple headache but an illness that requires medical treatment and consultation.

Available only for authorised users

Headache Clinical Practice Guideline Development Committee (2021) Clinical practice guideline for headache disorders 2021. Japanese Society of Neurology, Japanese Headache Society, and Japanese Society of Neurological Therapeutics (eds). Igaku-Shoin, Tokyo. p 23 and p 143

GBD (2015) Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(11):877–897. https://doi.org/10.1016/s1474-4422(17)30299-5CrossRef

Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17(1):15–22. https://doi.org/10.1046/j.1468-2982.1997.1701015.xCrossRef

Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y et al (2004) Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44(1):8–19. https://doi.org/10.1111/j.1526-4610.2004.04004.xCrossRef

Ando N, Fujimoto S, Ishikawa T, Teramoto J, Kobayashi S, Hattori A et al (2007) Prevalence and features of migraine in Japanese junior high school students aged 12–15 yr. Brain Dev 29(8):482–485. https://doi.org/10.1016/j.braindev.2007.01.003CrossRef

Goto M, Yokoyama K, Nozaki Y, Itoh K, Kawamata R, Matsumoto S et al (2017) Characteristics of headache in Japanese elementary and junior high school students: A school-based questionnaire survey. Brain Dev 39(9):791–798. https://doi.org/10.1016/j.braindev.2017.05.010CrossRef

Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S et al (2019) Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20(1):68. https://doi.org/10.1186/s10194-019-1012-1CrossRef

Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F (2019) Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia 39(12):1518–1534. https://doi.org/10.1177/0333102419851855CrossRef

Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T (2020) Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain 21(1):110. https://doi.org/10.1186/s10194-020-01180-9CrossRef

10.

Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T (2020) Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open 10(11):e038987. https://doi.org/10.1136/bmjopen-2020-038987CrossRef

11.

Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22(1):29. https://doi.org/10.1186/s10194-021-01243-5CrossRef

12.

Kotani K, Shimomura T, Ikawa S, Sakane N, Ishimaru Y, Adachi S (2004) Japanese with headache: suffering in silence. Headache 44(1):108–109. https://doi.org/10.1111/j.1526-4610.2004.t01-4-04020.xCrossRef

13.

Headache classification committee of the International Headache Society (IHS) (2018) The International classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202

14.

Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF (2013) The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22(5):1123–1133. https://doi.org/10.1007/s11136-012-0230-7CrossRef

15.

Speck RM, Shalhoub H, Ayer DW, Ford JH, Wyrwich KW, Bush EN (2019) Content validity of the Migraine-Specific Quality of Life Questionnaire version 2.1 electronic patient-reported outcome. J Patient Rep Outcomes 3(1):39. https://doi.org/10.1186/s41687-019-0138-xCrossRef

16.

Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 40(3):204–15. https://doi.org/10.1046/j.1526-4610.2000.00030.x

17.

Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353–365. https://doi.org/10.2165/00019053-199304050-00006CrossRef

18.

Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W (2003) A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61(3):375–382. https://doi.org/10.1212/01.wnl.0000078940.53438.83CrossRef

19.

Takeshima T, Sakai F, Suzuki N, Shimizu T, Igarashi H, Araki N et al (2015) A simple migraine screening instrument: validation study in Japan. Japanese Journal of Headache 42(1):134–144

Title: A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan
Authors: Fumihiko Sakai
Koichi Hirata
Hisaka Igarashi
Takao Takeshima
Takeo Nakayama
Hiromi Sano
Hiroyuki Kondo
Yoshiyuki Shibasaki
Nobuyuki Koga
Publication date: 01-12-2022
Publisher: Springer Milan
Keywords: Migraine
Headache
Triptan Drugs
Published in: The Journal of Headache and Pain / Issue 1/2022
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-022-01439-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study

Exploring alterations in sensory pathways in migraine

A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine

Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series

Disease- and headache-specific microRNA signatures and their predicted mRNA targets in peripheral blood mononuclear cells in migraineurs: role of inflammatory signalling and oxidative stress

Temporal characteristics of astrocytic activation in the TNC in a mice model of pain induced by recurrent dural infusion of inflammatory soup